Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial

Zhong-Zhen GUAN; Jian-Ming XU; Rong-Cheng LUO; Feng-Yi FENG; Li-Wei WANG; Lin SHEN; Shi-Ying YU; Yi BA; Jun LIANG; Dong WANG; Shu-Kui QIN; Jie-Jun WANG; Jing HE; Chuan QI; Rui-Hua XU.
Chinese Journal of Cancer ; (12): 682-689, 2011.
Artículo en Inglés | WPRIM | ID: wpr-294476

Documentos relacionados

  1. Indicaciones y Complicaciones del Implante de Marcapasos Endocárdico Percutáneo Definitivo en Paciente del Hospital Militar Central de El Salvador en el Periodo de Enero 2018 a Diciembre 2021
  2. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
  3. Foeniculum vulgare (hinojo): alternativa terapéutica femenina
  4. Prescripción e indicaciones de uso de fluoroquinolonas en un grupo de pacientes ambulatorios de Colombia
  5. Therapeutic living donor nephrectomy.
  6. Cannabis medicinal: puntos críticos para su uso clínico
  7. Porphyrin-lipid stabilized paclitaxel nanoemulsion for combined photodynamic therapy and chemotherapy.
  8. Platelet-rich plasma for androgenetic alopecia: Does it work? Evidence from meta analysis.
  9. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
  10. Pharmacological and residual effects in randomized placebo-controlled trials. A structural causal modelling approach.